AU2007284724B2 - For the identification, assessment, and treatment of patients with cancer therapy - Google Patents

For the identification, assessment, and treatment of patients with cancer therapy Download PDF

Info

Publication number
AU2007284724B2
AU2007284724B2 AU2007284724A AU2007284724A AU2007284724B2 AU 2007284724 B2 AU2007284724 B2 AU 2007284724B2 AU 2007284724 A AU2007284724 A AU 2007284724A AU 2007284724 A AU2007284724 A AU 2007284724A AU 2007284724 B2 AU2007284724 B2 AU 2007284724B2
Authority
AU
Australia
Prior art keywords
markers
expression
patient
marker
predictive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007284724A
Other languages
English (en)
Other versions
AU2007284724A1 (en
Inventor
Barbara M. Bryant
Andrew I. Damokosh
George Mulligan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2007284724A1 publication Critical patent/AU2007284724A1/en
Application granted granted Critical
Publication of AU2007284724B2 publication Critical patent/AU2007284724B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007284724A 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy Ceased AU2007284724B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83676406P 2006-08-10 2006-08-10
US60/836,764 2006-08-10
PCT/US2007/017716 WO2008021183A2 (en) 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy

Publications (2)

Publication Number Publication Date
AU2007284724A1 AU2007284724A1 (en) 2008-02-21
AU2007284724B2 true AU2007284724B2 (en) 2014-03-13

Family

ID=39082605

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007284724A Ceased AU2007284724B2 (en) 2006-08-10 2007-08-09 For the identification, assessment, and treatment of patients with cancer therapy

Country Status (7)

Country Link
US (1) US9500656B2 (enExample)
EP (1) EP2046973A4 (enExample)
JP (1) JP5725711B2 (enExample)
AU (1) AU2007284724B2 (enExample)
CA (1) CA2660275A1 (enExample)
MX (1) MX2009001489A (enExample)
WO (1) WO2008021183A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151967A1 (en) * 2008-05-28 2009-12-17 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
WO2010019921A2 (en) * 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
US20120149647A1 (en) * 2009-03-17 2012-06-14 Brody Jonathan R Methods for Assessing the Efficacy of Gemcitabine or Ara-C Treatment of Cancer Using Human Antigen R Levels
CA2758229A1 (en) * 2009-04-17 2010-10-21 University Health Network Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
EP2419540B1 (en) * 2009-04-18 2017-05-17 Merck Sharp & Dohme Corp. Methods and gene expression signature for assessing ras pathway activity
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US20120309640A1 (en) * 2009-10-08 2012-12-06 Torti Frank M Diagnostic and Prognostic Markers for Cancer
EP2524055A4 (en) * 2010-01-11 2013-06-05 Genomic Health Inc METHOD FOR THE USE OF GENE EXPRESSION FOR DETERMINING THE PROBABILITY OF CLINICAL EXERCISE OF KIDNEY CANCER
US20140322705A1 (en) * 2010-08-20 2014-10-30 Thomas Jefferson University Cancer diagnostic and cancer therapeutic
WO2013023132A1 (en) 2011-08-10 2013-02-14 Wake Forest University Health Sciences Diagnostic and prognostic markers for cancer
MX357429B (es) 2011-08-11 2018-07-09 Janssen Pharmaceutica Nv Predictores para el tratamiento del cáncer.
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
EP3387898B1 (en) * 2013-03-15 2020-05-13 Mayo Foundation for Medical Education and Research Identification and monitoring of monoclonal immunoglobulins by molecular mass
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3825420A1 (en) 2013-05-30 2021-05-26 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US20150287143A1 (en) * 2014-04-03 2015-10-08 John Hancock Life Insurance Company (U.S.A.) System and method for managing underwriting using a risk order approach
JP6759104B2 (ja) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
JP6675990B2 (ja) * 2014-05-20 2020-04-08 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 多発性骨髄腫の治療方法
EP3175242A4 (en) 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
CN108026164A (zh) 2015-09-24 2018-05-11 梅约医学教育与研究基金会 通过质谱鉴定免疫球蛋白游离轻链
JP6681475B2 (ja) * 2015-10-26 2020-04-15 サイフェローム がん患者のゲノム塩基配列変異情報と生存情報を利用したカスタマイズ型の薬物選択方法及びシステム
CN109863395B (zh) 2016-09-07 2023-05-23 梅约医学教育与研究基金会 分子量法鉴定和监测裂解免疫球蛋白
WO2018201083A1 (en) 2017-04-28 2018-11-01 University Of Southern California System and method for predicting survival time
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
CN110108878A (zh) * 2019-05-30 2019-08-09 四川大学华西医院 Eif2s1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004053066A2 (en) * 2002-12-06 2004-06-24 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05296999A (ja) * 1992-04-24 1993-11-12 Amano Pharmaceut Co Ltd グルココルチコイドの効果判定マーカーとしてのヒトリポコルチンｉ及びその定量法
JP2004248502A (ja) * 2000-10-05 2004-09-09 Takara Holdings Inc 癌悪性度の評価方法
CA2481485A1 (en) * 2002-04-04 2003-10-16 Ishihara Sangyo Kaisha, Ltd. Apparatus and method for analyzing data
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US7741035B2 (en) * 2004-05-21 2010-06-22 Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004053066A2 (en) * 2002-12-06 2004-06-24 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ball, N. S. and King, P. H., Clinical Cancer Research, 1997, Vol. 3, pages 1859-1865 *

Also Published As

Publication number Publication date
JP2010500565A (ja) 2010-01-07
EP2046973A4 (en) 2010-04-07
JP5725711B2 (ja) 2015-05-27
WO2008021183A9 (en) 2008-07-24
EP2046973A2 (en) 2009-04-15
MX2009001489A (es) 2009-02-18
WO2008021183A2 (en) 2008-02-21
US9500656B2 (en) 2016-11-22
CA2660275A1 (en) 2008-02-21
AU2007284724A1 (en) 2008-02-21
US20080064055A1 (en) 2008-03-13
WO2008021183A3 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
AU2007284724B2 (en) For the identification, assessment, and treatment of patients with cancer therapy
EP2687608B1 (en) Methods for the identification, assessment, and treatment of patients with cancer therapy
US20160312309A1 (en) Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
EP2904115B1 (en) Biomarkers and methods to predict response to inhibitors and uses thereof
JP5896593B2 (ja) プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
Julià et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis
EP2776586B1 (en) Biomarkers of response to proteasome inhibitors
US20240161868A1 (en) System and method for gene expression and tissue of origin inference from cell-free dna
US20240344138A1 (en) Targeted therapies in cancer
Mondello et al. Molecular clusters and tumor-immune drivers of IgM monoclonal gammopathies
Khazanov et al. Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profiling

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired